LANTERN PHARMA INC

Explore Lantern Pharma’s AI-driven oncology platform—cutting drug‑development time, cost, and failure rates in a live investor webinar on September 23.

Lantern Pharma’s FDA‑cleared STAR‑001 pediatric CNS trial and RADR® AI platform promise precision oncology breakthroughs, driving market interest and future growth potential.

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company leveraging AI, machine learning, and genomic data to optimize drug development and improve cancer treatment outcomes through targeted oncology therapies.

Lantern Pharma Inc.’s recent FDA clearances for its drug candidate LP-184 have sparked optimism, but the company’s financial health and the challenges of bringing a new treatment to market raise questions about its long-term viability.

Lantern Pharma Inc. has released its latest financials, showcasing a market capitalization of $39 million and a stock price of $3.86, despite experiencing significant stock price fluctuations in the past year.

Lantern Pharma Inc.’s ambitious use of AI and genomics in oncology treatment is promising, but its financial struggles and competitive market position raise doubts about its ability to deliver on its vision.

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company pioneering the use of AI and genomic data to develop personalized oncology therapies, with a focus on optimizing the drug development process and enhancing treatment efficacy.